We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EU Approves Venclyxto Combinations for Acute Myeloid Leukemia

EU Approves Venclyxto Combinations for Acute Myeloid Leukemia

Grey Approved Stamp
May 26, 2021

The European Commission has authorized Roche’s and AbbVie’s Venclyxto (venetoclax) combined with the hypomethylating agents azacitidine and decitabine for treating adults with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

The approval was supported by a phase 3 study showing Venclyxto plus azacytidine reduced the risk of death by 34 percent vs. azacytidine alone, with median overall survival of 14.7 months for the Venclyxto cohort vs. 9.6 months in participants who received azacytidine alone. In addition, a phase 1/2 study showed Venclyxto plus decitabine achieved a robust complete response in patients.

Venclyxto works by blocking the action of B-cell lymphoma protein-2 that promotes the spread of certain blood cancers and tumors.

The drug is marketed as Venclexta in the U.S., where the FDA has approved it for use in combination with azacitidine, decitabine or low-dose cytarabine for newly diagnosed AML in adults age 75 years or older who have comorbidities that rule out intensive chemotherapy.

View today's stories

Pharmaceuticals Submissions and Approvals

Upcoming Events

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

  • 08Mar

    Medical Device Cybersecurity: The Regulatory Landscape and How to Defend Your Practices During an Inspection

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Updates Smiths Medical CADD System Recall to Class I

  • Eisai’s New Alzheimer’s Drug Leqembi Hits the U.S. Market

  • Boston Scientific’s Single Use Ureteroscope Gets FDA Clearance

  • Gilead’s Trodelvy Gets Expanded Approval in Breast Cancer

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing